The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland
Completed
- Conditions
- Primary Biliary Cirrhosis
- Registration Number
- NCT02846896
- Lead Sponsor
- Benedetta Terziroli, MD
- Brief Summary
PBC is a rare, autoimmune, cholestatic liver disease with genetic and environmental pathogenetic factors. Data about epidemiology of PBC in Switzerland are completely lacking. Epidemiology can be a powerful tool in yielding important clues as to burden and etiology of diseases. In addition, the investigators study will be the first one carried out in the country on PBC, and therefore will raise disease awareness and create a network.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 501
Inclusion Criteria
- PBC patients living in Switzerland
Exclusion Criteria
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of PBC in Switzerland from 1.1.2005 until 31.12.2015
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What genetic factors like HLA-DRB1 contribute to PBC pathogenesis in Swiss populations?
How does UDCA effectiveness in PBC patients compare across Swiss and international epidemiological studies?
Which biomarkers such as AMA or anti-gp210 correlate with PBC progression in observational cohorts?
What adverse events like cholestasis or osteoporosis are prevalent in PBC patients according to NCT02846896 data?
What emerging therapies like obeticholic acid or farnesoid X receptor agonists are being explored for PBC in Switzerland?
Trial Locations
- Locations (1)
Fondazione Epatocentro Ticino
🇨🇭Lugano, Switzerland